These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25659724)

  • 1. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 2. New agents in the treatment of MDS.
    List AF
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623
    [No Abstract]   [Full Text] [Related]  

  • 3. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New tools and treatments in myelodysplastic syndromes].
    Cluzeau T; Fenaux P
    Rev Med Interne; 2013 Mar; 34(3):159-67. PubMed ID: 22766158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of MDS].
    Usuki K
    Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
    [No Abstract]   [Full Text] [Related]  

  • 7. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating new treatment options for MDS.
    Garcia-Manero G; Yang AS; Jagasia M
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):1-9; quiz 10-2. PubMed ID: 18185491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular target therapy for myelodysplastic syndrome].
    Morita Y; Tanaka H; Matsumura I
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():508-12. PubMed ID: 23513892
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The myelodysplastic syndromes: the era of understanding.
    Meers S
    Eur J Haematol; 2015 May; 94(5):379-90. PubMed ID: 25186093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDS: navigating the complex course.
    Fortenbaugh C
    ONS News; 2006; 21(8 Suppl):17-8. PubMed ID: 16925134
    [No Abstract]   [Full Text] [Related]  

  • 14. Myelodysplastic syndromes--many new drugs, little therapeutic progress.
    Tefferi A
    Mayo Clin Proc; 2010 Nov; 85(11):1042-5. PubMed ID: 20861462
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
    Oelschlaegel U; Westers TM; Mohr B; Kramer M; Parmentier S; Sockel K; Thiede C; Bornhäuser M; Ehninger G; van de Loosdrecht AA; Platzbecker U
    Haematologica; 2015 Mar; 100(3):e93-6. PubMed ID: 25425689
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

  • 18. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in myelodysplastic syndromes.
    List AF
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):271-2, 311. PubMed ID: 18496493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.